Analyst firms · H.C. Wainwright · CYTK

H.C. Wainwright CYTK price target and rating history

Cytokinetics Incorporated (CYTK) · Health Care

H.C. Wainwright rates Cytokinetics Incorporated (CYTK) Buy with a $69 price target, as of its latest action on Dec 21, 2021. It has published 4 rating actions on CYTK since July 2021, including 0 upgrades and 0 downgrades. Across 5 firms with a CYTK price target in the last 12 months, the median target is $95.

Current rating
Buy
Price target
$69
Median target, all firms
$95
Actions on CYTK
4

H.C. Wainwright price target on CYTK

$69$61$5320222023202420252026
H.C. Wainwright price target on CYTK, each point a stated target, July 2021 to December 2021.

Every H.C. Wainwright rating on CYTK

How other firms rate CYTK

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
UBSBuy$115Jun 29, 2026
CitigroupBuy$99May 19, 2026
Wells FargoOverweight$95Apr 10, 2026
BarclaysOverweight$87Jan 28, 2026
Goldman SachsBuy$95Dec 18, 2025

Questions about H.C. Wainwright and CYTK

What is H.C. Wainwright's price target for CYTK?
H.C. Wainwright's latest stated price target for Cytokinetics Incorporated (CYTK) is $69, from its action on Dec 21, 2021.
What is H.C. Wainwright's rating on CYTK?
H.C. Wainwright rates CYTK Buy, a bullish rating, as of Dec 21, 2021.
When did H.C. Wainwright last change its view on CYTK?
On Dec 21, 2021, H.C. Wainwright raises its price target to $69 from $62, keeps Buy.
How does H.C. Wainwright's CYTK target compare with other analysts?
Across 5 firms with a CYTK price target in the last 12 months, the median target is $95.

More CYTK rating histories

All H.C. Wainwright ratingsCYTK news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.